Tools for Measuring CTV Incrementality: Methods and Tradeoffs

Most CTV "lift" reports a pharma brand receives are matched comparisons between households that saw the ad and households that did not. They are cheap, fast, and often the default. They are also the weakest of the common designs. Before choosing a tool, it helps to know what each method needs and what it cannot see. The existing article on how to test incrementality in pharma CTV covers test design. This one compares the tools.

Comparing the tools for measuring CTV incrementality

Randomized holdouts and ghost ads

A holdout is the simplest idea in measurement. Pick a target list, randomly set aside 10 or 20 percent, do not serve them, and compare outcomes. On CTV the hard part is enforcement. The holdout has to be applied before targeting, at the household ID the platform actually uses. If you hold out on a hashed email but the platform serves by IP household, some holdout households will be served anyway through other IDs.

Ghost ads solve a different problem. In a normal holdout, you compare the whole treated group with the whole control group, but only a portion of the treated group ever sees an ad. Ghost ads let the platform flag control households at the moment they would have won an impression. You then compare exposed with "would have been exposed," which is a sharper comparison. The catch is that ghost ad logs are usually available inside one platform. A brand spread across five publishers gets five partial reads. The general principles of holdout test design for pharma media still apply.

Geo and matched market tests

When you cannot hold out individual households, hold out markets. Run CTV in a set of DMAs and not in comparable ones, then compare the change in outcomes. Geo tests have two big advantages for pharma. They capture effects that spill across devices and people in a household. They also work with prescription data aggregated by geography, which avoids some privacy questions about household-level matching.

The cost is statistical power. A hypothetical example: if weekly new-to-brand prescriptions vary by plus or minus 8 percent week to week in a typical market, a CTV effect of 2 percent will be hard to see with four test markets over eight weeks. You need more markets, a longer test, or a larger expected effect. Synthetic control methods help by building a weighted control from many markets. See synthetic control and matched market tests for pharma media.

Matched exposed versus unexposed panels

This is what most CTV outcomes reports do. An outcomes vendor takes the exposure file, matches exposed households to prescription, claims, or site visit data, then builds a comparison group of unexposed households that look similar on age, region, and other variables. The difference is reported as lift.

The problem is that exposure is not random. Households that see more CTV ads watch more streaming, which correlates with age, income, and household size. Those same traits correlate with health behavior. Matching controls for what is measured and nothing else. I would treat matched panel lift as a directional read, useful for comparing creative or publishers inside the same campaign, and not as proof that the channel caused the outcome. The distinction is spelled out in attributed vs. incremental prescriptions.

Marketing mix modeling

MMM estimates how much each channel contributed to outcomes over time, using spend and outcome data at a weekly or monthly grain. It is the only common tool that compares CTV with linear TV, search, and field promotion in one model. It also needs no household-level data, which helps with privacy.

MMM needs variation. If CTV spend was flat every week for two years, the model has nothing to learn from. It also struggles to separate CTV from linear when both move together. Use MMM to answer "how much should CTV get next year," and use controlled tests to answer "does this CTV tactic work." Marketing mix modeling for pharma covers when it beats Rx attribution.

What each tool needs from your data

1. An exposure file at the household or device level, with timestamps and the ID type the outcome vendor can match.
2. A control group defined before launch for holdouts and geo tests. Controls built after the fact are matched panels, whatever the report calls them.
3. An outcome source with enough volume: new-to-brand prescriptions, site actions, appointment requests. Privacy review of how the outcome data was de-identified and matched.
4. A pre-registered read plan with the primary metric, the window, and the minimum effect worth acting on.
5. Enough budget and time to reach statistical power. Small tests produce wide confidence intervals that get reported as "directional."

Choosing a tool for a pharma CTV program

For most brands, a mix works. Use a randomized holdout or ghost ads on the largest CTV partner, where you control the targeting. Run a geo test once or twice a year to validate the total CTV effect across partners. Feed both into MMM for annual planning. Use matched panel reports for in-flight optimization, labeled clearly as non-causal. That gives you a causal anchor and a fast read without pretending the fast read is causal. The series guide on CTV and OTT healthcare advertising puts these tools in the context of the other measurement layers.

Practical takeaway

On your next CTV plan, choose one partner where you control targeting and set up a randomized 15 percent household holdout before launch, using the same household ID the platform serves against. Write down the primary outcome, the read window, and the minimum lift that would change budget, and send that to the outcomes vendor before the first impression runs.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.